1Zarychanski R, Stuart T, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza(H1N1) virus infection[J]. Canadian Medical Association,2010,182(3):257-264.
2Greenbaum JA, Kotturi MF, Kim Y, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population[J]. PNAS, 2009, 106(48):20365- 20370.
3Cox NJ, Black RA, Kendal AP. Pathways of evolution of influenza A (H1N1) viruses from 1977 to 1986 as determined by oligonucleotide mapping and sequencing studies [J]. J.gen. Virol, 1989, 70:299-313.
4Sun XJ, Tse LV, Ferguson AD, et al. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus[J]. Virology, 2010, 84(17): 8683-8690.
5Bosch BJ, Bodewes R, Vries RP, et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets[J]. Virlogy, 2010, 84(10):10336-10374.
6Dunham E J, Dugan VG, Kaser EK, et al. Different evolutionary trajectories of european Avian-like and classical swine H1N1 influenza A viruses[J]. Virology, 2009, 11(7):1-3.
8Lin TW, Wang GY, Li AZ, et al. The hemagglutinin structure of an avian H,N, influenza A virus[J]. Vir.logy, 2009, 392(1): 73-81.
9Russell R J, Kerry PS, Stevens D J, et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion[J]. PNAS, 2008, 105(46):17736-17741.
3Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Ito T, Gorman O T, Kawaoka Y, et al. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins[J]. J Virol, 1991, 65(10): 5491- 5498.
7Lamb R A, Zebedee S L, Richardson C D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface[J]. Cell, 1985, 40:627-633.
8Tamura S,Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa[J]. Jpn J Infect Dis, 2004, 57:236-247.
9Frace A M, Klimov A I, Rowe T, et al. Modified M2 protein produce heterotypic immunity against influenza A virus[J]. Vaccine, 1999, 17: 2237-2244.
10Liu W L, Li H, Chen Y H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication[J]. FEMS Immunol Med Microbiol, 2003, 35 :141- 146.
4NEUMANN G, N ODA T, KAWAOKA Y. Emergence and pandemic potential of swine-origin HIN 1 influenza virus[J]. Nature, 2009, 459(7249): 931-9.
5SUN X, TSE LV, FERQUSON AD, et al. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic HINI influenza virus[J]. J Virol, 2010, 84(17): 8683-8690.
6BOSCH B J, BODEWEA R, DE VRIES RP, et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types orprotection against pandemic swine-origin 2009 A(H 1N 1 ) influenza virus infection in ferrets[J]. J Virol, 2010, 84( 19): 10366-10374.
7DUNHAM E J, DUQAN VG, KASER EK, et al. Different evolutionary trajectories of european Avian-like and classical swine H1N1 influenza A viruses[J]. J Virol, 2009, 83(11): 5485-5494.
8AUDSLEY J M, TANNOCK G A. The role of cell culture vaccines in the control of the next influenza pandemic[J]. Expert Opin Biol Ther, 2004, 4: 709-717.
9ZAMBON M. Cell culture for surveillance of influenza[J]. Dev Biol Stand, 1999, 98: 65-71.
10SCHILD G C, OXFORD J S, DE JONG J C, et al. Evidence for host-cell selection of influenza virus antigenic variants[J]. Nature, 1983, 303: 706-709.
